ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 20, 2021 14:21 ET
|
ImCheck Therapeutics SAS
ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
October 01, 2021 08:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 17, 2021 08:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021 First EVICTION data from checkpoint inhibitor-refractory solid tumor...
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 13, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
July 13, 2021 11:28 ET
|
ImCheck Therapeutics SAS
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells First published study showing the role and sequential interaction of...
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 26, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...
ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
April 15, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today...
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
April 09, 2021 00:01 ET
|
ImCheck Therapeutics SAS
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activationIncreased densities of activated and proliferating γδ,...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
November 11, 2020 07:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01 Preliminary EVICTION Phase I/IIa trial data shows...